Laboratory of Immunopathology Keizo Asami, Federal University of Pernambuco, Recife, PE, Brazil.
Pronto Socorro Cardiológico de Pernambuco (PROCAPE), University of Pernambuco, Recife, PE, Brazil.
Hypertens Res. 2022 Feb;45(2):364-368. doi: 10.1038/s41440-021-00784-1. Epub 2021 Dec 2.
There are concerns that hypertension control may decrease during the COVID-19 pandemic. This study evaluated the impact of the COVID-19 pandemic on office blood pressure (OBP) and home blood pressure monitoring (HBPM) control in a large Brazilian nationwide sample. The results of an adjusted spline analysis evaluating the trajectory of OBP and HBPM control from 01/Jan/2019 to 31/Dec/2020 among independent participants who were untreated (n = 24,227) or treated (n = 27,699) with antihypertensive medications showed a modest and transient improvement in OBP control among treated individuals, which was restricted to the early months following the COVID-19 pandemic outbreak. Furthermore, slight reductions in OBP and HBPM values were detected in the early months following the COVID-19 pandemic outbreak among treated (n = 987) participants for whom blood pressure measurements before and during the pandemic were available, but not among untreated (n = 495) participants. In conclusion, we found no major adverse influence of the COVID-19 pandemic on OBP and HBPM control in a large nationwide sample.
有人担心，在 COVID-19 大流行期间，高血压的控制可能会下降。本研究评估了 COVID-19 大流行对巴西全国范围内大型样本中办公室血压（OBP）和家庭血压监测（HBPM）控制的影响。在一项调整后的样条分析中，评估了从 2019 年 1 月 1 日至 2020 年 12 月 31 日期间，未经治疗（n=24227）或接受降压药物治疗（n=27699）的独立参与者的 OBP 和 HBPM 控制轨迹，结果显示，治疗组的 OBP 控制有适度和短暂的改善，这种改善仅限于 COVID-19 大流行爆发后的早期几个月。此外，在 COVID-19 大流行爆发后的早期几个月，对于有血压测量数据（n=987）的治疗组参与者（n=987），OBP 和 HBPM 值略有下降，但在未经治疗组（n=495）参与者中未发现这种下降。总之，我们在一个大型全国性样本中没有发现 COVID-19 大流行对 OBP 和 HBPM 控制的重大不利影响。
